NovaBridge Biosciences (NBP)

NovaBridge Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-88.34	-22.23	-207.73	-371.05	-367.02
Depreciation & Amortization	0.86	0.98	1.06	1.42	4.84
Other Amortization	-	-	-	2.25	0.12
Loss (Gain) From Sale of Assets	0.02	-0.01	-	-0.03	0.05
Asset Writedown & Restructuring Costs	42.07	1.25	23.04	-	-
Loss (Gain) From Sale of Investments	1.75	-	-0.22	-1.9	-4.78
Loss (Gain) on Equity Investments	-	1.04	11.4	64.71	57.91
Stock-Based Compensation	5.97	-1.95	10.24	13.15	95.8
Other Operating Activities	-	-28.93	126.63	224.78	-2.21
Change in Accounts Receivable	-	-	-	1.55	11.18
Change in Inventory	-	-	-	-	-4.29
Change in Unearned Revenue	-	-	-	-	34.08
Change in Other Net Operating Assets	17.07	-2.81	-37.12	15.55	21.13
Operating Cash Flow	-20.6	-106.63	-146.5	-90.22	-153.18
Capital Expenditures	-0.01	-0.05	-0.16	-2.09	-4.71
Sale of Property, Plant & Equipment	0.05	0.06	-	-	-
Investment in Securities	104.93	-136.03	-15	-3.09	-109.76
Investing Cash Flow	104.97	-136.02	-15.16	-5.18	-114.47
Issuance of Common Stock	61.91	-	0.41	6.92	115.31
Repurchase of Common Stock	-	-0.34	-8.64	-3.01	-
Other Financing Activities	-4.19	-	-	-	-21.82
Financing Cash Flow	57.73	-0.34	-8.24	3.91	93.49
Foreign Exchange Rate Adjustments	0.28	0.57	5.2	14.2	-20.27
Net Cash Flow	142.37	-242.4	-164.7	-77.3	-194.43
Free Cash Flow	-20.6	-106.68	-146.66	-92.32	-157.89
Free Cash Flow Margin	-	-	-23206.33%	-	-1139.46%
Free Cash Flow Per Share	-0.21	-1.31	-1.76	-1.12	-2.08
Cash Interest Paid	-	-	-	0.1	-
Cash Income Tax Paid	-	-	-	-	1.43
Levered Free Cash Flow	-37.11	-68.15	-58.84	47.43	-96.12
Unlevered Free Cash Flow	-37.11	-68.15	-58.84	47.43	-96.12
Change in Working Capital	17.07	-2.81	-37.12	17.09	62.1

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q